Detection, Monitoring, and Molecular Characterization of Leukemic Stem Cells From Patients With Chronic Myeloid Leukemia (CML) Undergoing Therapy With Nilotinib
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2018
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 30 May 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 01 Nov 2017 Status changed from not yet recruiting to recruiting.
- 10 Feb 2015 New trial record